Successful Treatment of Annular Atrophic Lichen Planus With Adalimumab
Author Information
Author(s): Khodeir Joe, Ohanian Paul, Ohanian Marielena
Primary Institution: University of Balamand, Faculty of Medicine and Medical Sciences
Hypothesis
Can adalimumab effectively treat resistant annular atrophic lichen planus in patients with prior treatment failures?
Conclusion
Adalimumab may be an effective systemic treatment for resistant annular atrophic lichen planus, leading to significant improvement in patients who have not responded to other therapies.
Supporting Evidence
- Adalimumab is commonly used in dermatology for chronic inflammatory skin conditions.
- The patient had a significant improvement after 8 weeks of adalimumab treatment.
- Prior treatments included topical steroids and oral medications, which were ineffective.
Takeaway
A woman with a rare skin condition got better after taking a medicine called adalimumab, which helped her when other treatments didn't work.
Methodology
The patient was treated with an 80 mg loading dose of adalimumab followed by 40 mg biweekly, with biopsies confirming the diagnosis.
Potential Biases
Potential bias due to the lack of a control group and reliance on subjective improvement measures.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
56-year-old female with a history of ischemic stroke and chronic skin condition.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website